CD8A and neoplasm: Furthermore, vaccination with autologous tumor lysate-pulsed dendritic cells (DC) and toll-like receptor (TLR) agonists in a phase I clinical trial resulted in the enhancement of tumor-infiltrating CD8+ T cells and increased survival among a subset of patients[3].